{"commentary":{"count":37,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":30,"youtube":4,"x_video":2,"podcast":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06100874\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT06100874","nct_id":"NCT06100874","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06100874. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants will complete the following:\n\n* Baseline visit with assessments.\n* CT or MRI scans every 9 weeks for 27 weeks and then every 12 weeks.\n* Echocardiogram or MUGA scan every 12 weeks for 24 weeks and then every 16 weeks.\n* Cycle 1 through Cycle 2:\n\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* Cycle 2:\n\n  * Day 1: Optional tumor biopsy\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* Cycle 3 through End of Treatment:\n\n  * Days 1 and 8 of 21 day cycle: Predetermined dose of Sacituzumab govitecan 1x daily.\n  * Day 1 of 21 day cycle: Predetermined dose of Trastuzumab either intravenously or subcutaneously 1x daily.\n* End of treatment:\n\n  * Follow up visits every 6 months.","label":"Sacituzumab Govitecan + Trastuzumab (or Biosimilar)","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences"],"completion_date":{"date":"2027-11-30","type":"ESTIMATED"},"conditions":["Her 2 Positive Breast Cancer","Breast Cancer Female","Breast Cancer Metastatic"],"enrollment":{"count":28,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sacituzumab Govitecan","type":"DRUG"},{"name":"Trastuzumab","type":"DRUG"},{"name":"Trastuzumab and Hyaluronidase-oysk","type":"DRUG"}],"last_update":"2026-02-24","lead_sponsor":"Adrienne G. Waks","official_title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-02-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR)","timeFrame":"3 years"}],"references":[],"start_date":{"date":"2023-11-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","url":"https://clinicaltrials.gov/study/NCT06100874"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06100874"}